NPHC Nutra Pharma Corp.
Distress ·
Nutra Pharma filed a Form 12b-25 notice on August 14, 2026, saying its quarterly report for the period ended June 30, 2026 would be late. Its cash at December 31, 2025 was $12,181.
We have not published a story on Nutra Pharma yet. When there is news, it will appear here.
Nutra Pharma Corp. is a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases and pain. It was incorporated in California on February 1, 2000, and launched its first consumer product, Cobroxin, in October 2009. Its current over-the-counter pain relievers include Nyloxin and Nyloxin Extra Strength, which use Asian cobra venom as the active ingredient, along with Pet Pain-Away for cats and dogs, Equine Pain-Away for horses and Luxury Feet for foot pain. The company says it has developed two drug candidates. RPI-78M is aimed at neurological and autoimmune diseases, including Multiple Sclerosis, Adrenomyeloneuropathy, Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis and Myasthenia Gravis. RPI-MN is aimed at viral diseases, including HIV/AIDS and Herpes. The company was granted FDA orphan designation for the treatment of pediatric Multiple Sclerosis in September 2015. It also says it is pursuing its technology as a possible nerve agent countermeasure. The text states that its potential products are subject to FDA approval.
| Product or program | What it is | Stage |
|---|---|---|
| Nyloxin and Nyloxin Extra Strength | OTC topical gel and oral spray for moderate to severe chronic pain | currently marketed |
| Pet Pain-Away | OTC pain reliever for cats and dogs | launched December 2014 |
| Equine Pain-Away | OTC topical pain reliever for horses | launched October 2019 |
| Luxury Feet | OTC pain reliever for foot pain from high heels | launched March 2021 |
| RPI-78M | Drug candidate for neurological and autoimmune diseases | subject to FDA approval |
| RPI-MN | Drug candidate for viral diseases including HIV/AIDS and herpes | subject to FDA approval |
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$2.0 million | -$1.3 million |
| Cash from operations | -$1.2 million | -$423,959 |
| Cash and equivalents | $12,181 | $36,447 |
| Short-term investments | $17,600 | $17,600 |
Our latest story on this, dated Aug 14, 2026: "Nutra Pharma files late-filing notice for its June 30, 2026 quarterly report". The story links the filing or release it is based on. Read the story.
Nutra Pharma Corp. trades under the ticker NPHC on OTC.
Nutra Pharma Corp. is listed on OTC.
The SEC Central Index Key (CIK) for Nutra Pharma Corp. is 1119643. Its filings are on SEC EDGAR.
7,159,727,214 shares as of 2026-08-19, per the cover page of its 10-Q filed 2026-08-19.
Our directory records Nutra Pharma Corp. under United States.
Our directory classifies Nutra Pharma Corp. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Nutra Pharma Corp. is US67060U2087.
aibio.space lists Nutra Pharma Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as CA.
Nutra Pharma Corp. is a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases and pain. It was incorporated in California on February 1, 2000, and launched its first consumer product, Cobroxin, in October 2009.
Nyloxin and Nyloxin Extra Strength: OTC topical gel and oral spray for moderate to severe chronic pain Stage: currently marketed.
Pet Pain-Away: OTC pain reliever for cats and dogs Stage: launched December 2014.
Nutra Pharma Corp. reported a net loss of $2.0 million for the fiscal year ended Dec 31, 2025, and used $1.2 million of cash in operations, per its annual report to the SEC.
$29,781 in cash and short-term investments at Dec 31, 2025, per its 10-K.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio